PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity

Thrombosis Research

Volumn 132, Issue 4, 2013, Pages 444-449

  Li, Xiaoqi ^a   Zhang, Lanning ^a   Chen, Xi ^a   Qu, Fei ^a   Li, Jiayue ^a   Ma, Cong ^a   Yang, Jie ^a   Xu, Bin ^a   Wang, Hongjuan ^a   Xu, Qiang ^a   Zhang, Yuxiao ^a   Li, Yang ^a   Lu, Caiyi ^a   Yin, Tong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

clopidogrel; CYP2C19; platelet; PON1; responsiveness

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL EVALUATION; COHORT ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS; WILD TYPE;

CLOPIDOGREL; CYP2C19; PLATELET; PON1; RESPONSIVENESS;

ANGINA, UNSTABLE; ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; BLOOD PLATELETS; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84885186428     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.08.004     Document Type: Article

References (51)

1. R.S. Wright, J.L. Anderson, C.D. Adams, C.R. Bridges, D.E. Casey Jr., and S.M. Ettinger American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 e215 e367
2. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
3. C. Combescure, P. Fontana, N. Mallouk, P. Berdague, C. Labruyere, and I. Barazer Clopidogrel, Vascular IEM-aSG. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 8 2010 923 933
4. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, and D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
5. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, and V. Ramakrishnan Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207
6. M. Cattaneo The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects Blood 117 2011 2102 2112
7. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Working Group on High On-Treatment Platelet R. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
8. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
9. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, and C.S. Ernest II Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
10. K. Umemura, T. Furuta, and K. Kondo The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects J Thromb Haemost 6 2008 1439 1441
11. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
12. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
13. P. Fontana, J.S. Hulot, P. De Moerloose, and P. Gaussem Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects J Thromb Haemost 5 2007 2153 2155
14. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
15. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
16. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
17. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
18. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
19. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dorrler Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
20. H.J. Bouman, E. Schomig, J.W. van Werkum, J. Velder, C.M. Hackeng, and C. Hirschhauser Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
21. D. Sibbing, W. Koch, S. Massberg, R.A. Byrne, J. Mehilli, and S. Schulz No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 2011 1605 1613
22. P. Fontana, R. James, I. Barazer, P. Berdague, J.F. Schved, and M. Rebsamen Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study J Thromb Haemost 9 2011 1664 1666
23. D. Trenk, W. Hochholzer, M.F. Fromm, O. Zolk, C.M. Valina, and C. Stratz Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement Circ Cardiovasc Genet 4 2011 429 436
24. O. Rideg, A. Komocsi, T. Magyarlaki, M. Tokes-Fuzesi, A. Miseta, and G.L. Kovacs Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention Pharmacogenomics 12 2011 1269 1280
25. J.S. Hulot, J.P. Collet, G. Cayla, J. Silvain, F. Allanic, and A. Bellemain-Appaix CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients Circ Cardiovasc Interv 4 2011 422 428
26. J.P. Lewis, A.S. Fisch, K. Ryan, J.R. O'Connell, Q. Gibson, and B.D. Mitchell Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response Clin Pharmacol Ther 90 2011 568 574
27. J.T. Delaney, A.H. Ramirez, E. Bowton, J.M. Pulley, M.A. Basford, and J.S. Schildcrout Predicting clopidogrel response using DNA samples linked to an electronic health record Clin Pharmacol Ther 91 2012 257 263
28. G. Campo, P. Ferraresi, J. Marchesini, F. Bernardi, and M. Valgimigli Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention J Thromb Haemost 9 2011 2106 2108
29. G. Cayla, J.S. Hulot, S.A. O'Connor, A. Pathak, S.A. Scott, and Y. Gruel Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis JAMA 306 2011 1765 1774
30. T. Simon, P.G. Steg, L. Becquemont, C. Verstuyft, S. Kotti, and F. Schiele Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction Clin Pharmacol Ther 90 2011 561 567
31. M.I. Mackness Why plasma should not be used to study paraoxonase Atherosclerosis 136 1998 195 196
32. J. Camps, J. Joven, B. Mackness, M. Mackness, D. Tawfik, and D. Draganov Paraoxonase-1 and clopidogrel efficacy Nat Med 17 2011 1041 1042 [author reply 2-4]
33. J.A. Talameh, and H.L. McLeod PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication? Clin Pharmacol Ther 90 2011 771 774
34. W.M. Samara, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The difference between clopidogrel responsiveness and posttreatment platelet reactivity Thromb Res 115 2005 89 94
35. M.D. Linden, H. Tran, R. Woods, and A. Tonkin High platelet reactivity and antiplatelet therapy resistance Semin Thromb Hemost 38 2012 200 212
36. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King III, J.L. Anderson, and E.M. Antman 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
37. S.B. King III 2009 update of the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and guidelines on percutaneous coronary intervention: what should we change in clinical practice? Pol Arch Med Wewn 120 2010 6 8
38. P.D. Patel, and R.R. Arora Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction Am J Ther 17 2010 e24 e40
39. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
40. L. Zhang, Y. Chen, Y. Jin, F. Qu, J. Li, and C. Ma Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients Thromb Res 2013 10.1016/j.thromres.2013.05.006
41. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
42. M.P. Petraki, P.T. Mantani, and A.D. Tselepis Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides Curr Pharm Des 15 2009 3146 3166
43. L.G. Costa, T.B. Cole, G.P. Jarvik, and C.E. Furlong Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism Annu Rev Med 54 2003 371 392
44. V. Ancrenaz, J. Desmeules, R. James, P. Fontana, J.L. Reny, and P. Dayer The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro Br J Pharmacol 166 2012 2362 2370
45. P.M. Dansette, J. Rosi, G. Bertho, and D. Mansuy Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer Chem Res Toxicol 25 2012 348 356
46. A.D. Tselepis, M.E. Tsoumani, K.I. Kalantzi, A.A. Dimitriou, C.C. Tellis, and I.A. Goudevenos Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy J Thromb Haemost 9 2011 2371 2378
47. J.L. Reny, C. Combescure, Y. Daali, P. Fontana, and Group PONM-A Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis J Thromb Haemost 10 2012 1242 1251
48. H.L. Li, D.P. Liu, and C.C. Liang Paraoxonase gene polymorphisms, oxidative stress, and diseases J Mol Med (Berl) 81 2003 766 779
49. T. Bhattacharyya, S.J. Nicholls, E.J. Topol, R. Zhang, X. Yang, and D. Schmitt Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA 299 2008 1265 1276
50. M.D. Linden, M.I. Furman, A.L. Frelinger III, M.L. Fox, M.R. Barnard, and Y. Li Indices of platelet activation and the stability of coronary artery disease J Thromb Haemost 5 2007 761 765
51. X.F. Tang, J. Wang, J.H. Zhang, X.M. Meng, B. Xu, and S.B. Qiao Effect of the CYP2C19*2 and*3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention Eur J Clin Pharmacol 69 2013 1103 1112